Clinical Trial Update: DE-117 Spectrum 5 Study [Phase 3]

View source ↗

Summary

Phase 3 trial update for DE-117 Spectrum 5 in primary open-angle glaucoma and ocular hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• DE-117 Spectrum 5 (DE-117 Spectrum 5)

Snippet

Sponsor: Santen Inc. | Conditions: Primary Open-angle Glaucoma and Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2023-08-30